Last updated: Jun 27, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06904066 | 1 | Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies | Patient-specific neoantigen TCRs -- autologous T cell receptor (TCR) transduced T cells |
| NCT06615479 | 3 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | GPRC5D -- CAR-T cell therapy |
| NCT06107738 | 2 | Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma | Cereblon modulator + CD38 -- immunomodulation and antibody-dependent cellular cytotoxicity (IMiD + monoclonal antibody) |
| NCT07649681 | — | Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention | Unknown mechanism |
| NCT07671287 | 3 | GMMG-HD11/DSMM XXI/64007957MMY3010 | BCMA -- bispecific antibody (Teclistamab); CD38 -- monoclonal antibody (Daratumumab); Multiple targets including cereblon -- immunomodulatory agent (Lenalidomide); Proteasome -- proteasome inhibitor (Bortezomib); Glucocorticoid receptor -- corticosteroid (Dexamethasone) |
| Sponsor | Recruiting trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 24 |
| Janssen Research & Development, LLC | 14 |
| Regeneron Pharmaceuticals | 11 |
| Memorial Sloan Kettering Cancer Center | 11 |
| Washington University School of Medicine | 10 |
Countries/regions with the most active trial sites for multiple myeloma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Jun 1, 2027 | NCT04579523 | ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma | CD38 -- radioimmunotherapy (211At-OKT10-B10) |
| Dec 1, 2026 | NCT07600151 | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma | CD38 -- monoclonal antibody (isatuximab); Proteasome -- proteasome inhibitor (bortezomib); Cereblon -- immunomodulatory agent (lenalidomide); Glucocorticoid receptor -- corticosteroid (dexamethasone); Unknown mechanism (etentamig) |
| Oct 23, 2026 | NCT07609706 | A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment | BCMA -- antibody-drug conjugate (Belantamab mafodotin); Proteasome -- proteasome inhibitor (Bortezomib); Glucocorticoid receptor -- corticosteroid agonist (Dexamethasone) |
| Sep 1, 2026 | NCT07611149 | Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma | BCMA -- chimeric antigen receptor T-cell therapy (CAR T-cell) |
| Jul 1, 2026 | NCT06904066 | Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies | Patient-specific neoantigen TCRs -- autologous T cell receptor (TCR) transduced T cells |
| Jul 1, 2026 | NCT05976555 | Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma | BCMA + TGF-beta -- CAR-T with TGF-beta resistance |
| Jul 2026 | NCT07479979 | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | XPO1 -- selective inhibitor of nuclear export (selinexor); Proteasome -- proteasome inhibitor (carfilzomib); CD38 -- monoclonal antibody (isatuximab) |
| Jul 2026 | NCT07221032 | FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma | NKG2D -- CAR-T + CD38 -- monoclonal antibody (daratumumab) |
You've seen the multiple myeloma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.